|
|
Other links at Articles > Gastroenterology |
| 4. |
Treatment-Resistant HCV Patients Respond to Protease Inhibitor-Based Therapy
|
|
|
The investigational protease inhibitor telaprevir (Tibotec and Vertex Pharmaceuticals), added to standard treatment for hepatitis C virus (HCV) infection, produced a sustained virologic response in more than half of patients with treatment-refractory disease, late-breaking clinical trial results show. Reuters Health Information
|
|
|